What are the limitations of the agvhd grading?

While the agvhd grading is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the agvhd grading to ensure safe bedside use and optimal diagnostic accuracy.

How does the agvhd grading compare to other hematology scores?

The agvhd grading is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the agvhd grading free to use?

Yes. OpiCalc provides the agvhd grading completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

OpiCalc

927 Clinical Tools

OpiCalc

4Ts Score (HIT)aaIPI (Age-adjusted IPI)ABC Score (Massive Transfusion)Absolute Neutrophil Count Age-adjusted D-dimer Threshold aGvHD Grading (Glucksberg/MAGIC)AL Amyloidosis Staging (Mayo)Anti-Xa Monitoring Interpreter Antiphospholipid Syndrome Classification Binet / Rai Staging (CML)Blood Volume Calculator Caprini VTE Risk CISNE Score CLL-IPI Coombs-Negative Haemolysis Checklist Corrected Reticulocyte Count CRS Grading (ASTCT 2019)DAT Interpretation Algorithm Deauville Score Interpreter DIC Score (ISTH)DIPSS (MF)DIPSS-Plus (MF)DOAC Dose Selector DOAC Renal Dose Adjustment DRI (Disease Risk Index)Durie-Salmon Staging (historical)EBMT Risk Score ELN 2022 AML Risk Classification ELTS Score (CML)England & Fraser Index EUTOS Score (CML)Expected Hb Rise per RBC Unit Factor Inhibitor Bethesda Titre Interpreter Febrile Neutropaenia Risk (MASCC)Fibrinogen Replacement FLIPI (Follicular Lymphoma IPI)FLIPI-2 French TTP Score GAPSS (Global APS Score)Haemophilia Severity Classification HbS Percentage Target Calculator HCT-CI (Comorbidity Index)HEP Score Heparin Nomogram (Weight-based)Hepatic Iron Index HERDOO2 Rule HFE Haemochromatosis Risk Estimator ICANS Grading (ASTCT 2019)IMWG Response Criteria (Myeloma)IPI (International Prognostic Index)IPSID / Lugano Classification IPSS-M (Molecular IPSS)IPSS-R (Revised IPSS for MDS)Iron Deficit Calculator (Ganzoni Formula)ISS (Myeloma)ISTH Bleeding Assessment Tool (BAT)ISTH Non-Overt DIC Score ITP Bleeding Score iwCLL Response Criteria (2018)IWG ITP Response Criteria JAK2V617F Allele Burden Interpreter Karnofsky Performance Scale Leucostasis Risk Threshold Lupus Anticoagulant (LAC) Reporting Framework MAGIC aGvHD Biomarker Score MCV-based Anaemia Algorithm Mentzer Index MIPI (MCL IPI)MIPSS70+ v2.0 (MF)Mixing Study Interpretation MRD Assessment Threshold Interpreter mSMART 3.0 (Myeloma)MTP Activation Criteria NCCN-IPI NIH Chronic GvHD Scoring NTDT Iron Burden Estimator Padua RAM PBT (Paediatric BAT)PCNSL MSKCC Score PERC Rule Perioperative Anticoagulation Bridging PESI Score (PE Mortality)PLASMIC Score Platelet Increment Calculator (CCI)PNH Clone Size Interpreter R-IPI (Revised IPI)R-ISS (Revised ISS)Reticulocyte Index (RPI)Revised Geneva Score (PE)Revised Response Criteria (NHL)Revised Zubrod / ECOG Performance Shine & Lal Index Sickle Cell Disease Risk (TCD)SLiM-CRAB Criteria SOKAL Score (CML)Sokal/EUTOS/ELTS Comparison sPESI (Simplified PESI)TACO Risk Score Thalassaemia Transfusion Threshold Thrombocytopaenia Differential Thrombophilia Screening Eligibility Algorithm Time in Therapeutic Range (TTR)TLS Risk Classification Transferrin Saturation Calculator Vienna Prediction Model von Willebrand Factor Activity Interpreter Warfarin Dose Calculator Wells Score (DVT)Wells Score (PE)WHO 2022 AML Classification Mapper WHO Bleeding Scale YEARS Algorithm

aGvHD Grading (Glucksberg/MAGIC)

aGvHD Grading: Hierarchical clinical grading based on organ-specific involvement. Grade II–IV usually warrants systemic immunosuppression.

Skin (Rash)

Liver (Bilirubin)

GI (Diarrhea)

Composite Clinical Grade

-

Clinical aGvHD criteria not met based on selected organ stages.

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Standardized clinical assessment of patients following hematopoietic cell transplant who develop clinical signs of acute Graft-vs-Host Disease (aGvHD).

To guide treatment decisions (e.g., initiating corticosteroids for Grade ≥ II disease).

Ensuring consistent toxicity reporting in clinical trials.

Patient Population

Patients who have received allogeneic hematopoietic cell transplantation.

Timing

Historically, "acute" GvHD was restricted to within 100 days of HCT. Current consensus (NIH 2014) defines aGvHD by clinical phenotype (e.g., maculopapular rash, secretory diarrhea, cholestatic jaundice), regardless of the time elapsed since transplant.

Section 2

Formula & Logic

Individual Organ Staging (1 - 4)

Stage	Skin (Rash)	Liver (Bili mg/dL)	GI (Diarrhea)
1	< 25% BSA	2.0 - 3.0	500 - 1000 mL/day
2	25 - 50% BSA	3.1 - 6.0	1001 - 1500 mL/day
3	> 50% BSA	6.1 - 15.0	> 1500 mL/day
4	Bullae/Desquam.	> 15.0	Severe Pain / Ileus

Overall Clinical Grade (I - IV)

Grade	Skin Stage	Liver Stage	GI Stage	Severity
I	1 – 2	0	0	Mild
II	3 OR	1 OR	1	Moderate
III	—	2 – 3 OR	2 – 4	Severe
IV	4 OR	4	—	Life-threatening

Section 3

Pearls/Pitfalls

BSA Estimators

When assessing skin aGvHD, use the Rule of Nines for rapid estimation. A Stage 1 rash ( < 25%) typically involves the palms, soles, ears, and neck before spreading to the trunk.

Bowel Output in Pediatrics

For pediatric patients, substitute volume thresholds with: Stage 1 (> 10 mL/kg/d), Stage 2 (> 15 mL/kg/d), Stage 3 (> 20 mL/kg/d).

Section 4

Evidence Appraisal

Primary Score

Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors.

Glucksberg H et al. • Transplantation. 1974;18(4):295-304.

View Source

International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the MAGIC Consortium.

Harris AC et al. • Biology of Blood and Marrow Transplantation. 2016;22(1):4-10.

View Source

Section 5

Literature

Legacy

Named after the original Glucksberg classification (1974), recent MAGIC refinements have standardized how diarrhea volume is measured and how to handle biopsy-proven vs. clinical-only presentations.

Last Comprehensive Review: 2026

Related Hematology Tools

mSMART 3.0

SLiM-CRAB Criteria

Durie-Salmon Staging

AL Amyloidosis Staging

HCT-CI

EBMT Risk Score

DRI

MAGIC aGvHD Biomarker Score

CRS Grading

ICANS Grading

Have feedback about this calculator?Let us know.

aGvHD Grading (Glucksberg/MAGIC)

aGvHD Grading: Hierarchical clinical grading based on organ-specific involvement. Grade II–IV usually warrants systemic immunosuppression.

Skin (Rash)

Liver (Bilirubin)

GI (Diarrhea)

Composite Clinical Grade

-

Clinical aGvHD criteria not met based on selected organ stages.

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Standardized clinical assessment of patients following hematopoietic cell transplant who develop clinical signs of acute Graft-vs-Host Disease (aGvHD).

To guide treatment decisions (e.g., initiating corticosteroids for Grade ≥ II disease).

Ensuring consistent toxicity reporting in clinical trials.

Patient Population

Patients who have received allogeneic hematopoietic cell transplantation.

Timing

Section 2

Formula & Logic

Individual Organ Staging (1 - 4)

Stage	Skin (Rash)	Liver (Bili mg/dL)	GI (Diarrhea)
1	< 25% BSA	2.0 - 3.0	500 - 1000 mL/day
2	25 - 50% BSA	3.1 - 6.0	1001 - 1500 mL/day
3	> 50% BSA	6.1 - 15.0	> 1500 mL/day
4	Bullae/Desquam.	> 15.0	Severe Pain / Ileus

Overall Clinical Grade (I - IV)

Grade	Skin Stage	Liver Stage	GI Stage	Severity
I	1 – 2	0	0	Mild
II	3 OR	1 OR	1	Moderate
III	—	2 – 3 OR	2 – 4	Severe
IV	4 OR	4	—	Life-threatening

Section 3

Pearls/Pitfalls

BSA Estimators

When assessing skin aGvHD, use the Rule of Nines for rapid estimation. A Stage 1 rash ( < 25%) typically involves the palms, soles, ears, and neck before spreading to the trunk.

Bowel Output in Pediatrics

For pediatric patients, substitute volume thresholds with: Stage 1 (> 10 mL/kg/d), Stage 2 (> 15 mL/kg/d), Stage 3 (> 20 mL/kg/d).

Section 4

Evidence Appraisal

Primary Score

Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors.

Glucksberg H et al. • Transplantation. 1974;18(4):295-304.

View Source

International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the MAGIC Consortium.

Harris AC et al. • Biology of Blood and Marrow Transplantation. 2016;22(1):4-10.

View Source

Section 5

Literature

Legacy

Named after the original Glucksberg classification (1974), recent MAGIC refinements have standardized how diarrhea volume is measured and how to handle biopsy-proven vs. clinical-only presentations.

Last Comprehensive Review: 2026

Related Hematology Tools

mSMART 3.0

SLiM-CRAB Criteria

Durie-Salmon Staging

AL Amyloidosis Staging

HCT-CI

EBMT Risk Score

DRI

MAGIC aGvHD Biomarker Score

CRS Grading

ICANS Grading

Have feedback about this calculator?Let us know.